| 前收盘价格 | 20.21 |
| 收盘价格 | 20.07 |
| 成交量 | 699,169 |
| 平均成交量 (3个月) | 931,185 |
| 市值 | 1,438,347,008 |
| 价格/销量 (P/S) | 15.50 |
| 股市价格/股市净资产 (P/B) | 2.91 |
| 52周波幅 | |
| 利润日期 | 5 Aug 2026 |
| 营业毛利率 | -163.17% |
| 营业利益率 (TTM) | -131.93% |
| 稀释每股收益 (EPS TTM) | -3.04 |
| 季度收入增长率 (YOY) | 104.60% |
| 总债务/股东权益 (D/E MRQ) | 34.73% |
| 流动比率 (MRQ) | 5.89 |
| 营业现金流 (OCF TTM) | -161.55 M |
| 杠杆自由现金流 (LFCF TTM) | -84.53 M |
| 资产报酬率 (ROA TTM) | -11.42% |
| 股东权益报酬率 (ROE TTM) | -34.05% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Xencor, Inc. | 混合的 | 看涨 |
AIStockmoo 评分
0.2
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | -5.0 |
| 技术平均移动指标 | 1.5 |
| 技术振荡指标 | 4.0 |
| 平均 | 0.17 |
|
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 1.24% |
| 机构持股比例 | 111.90% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Primecap Management Co/Ca/ | 31 Mar 2026 | 10,338,022 |
| Bvf Inc/Il | 31 Mar 2026 | 7,133,720 |
| Rtw Investments, Lp | 31 Mar 2026 | 6,777,461 |
| Ecor1 Capital, Llc | 31 Mar 2026 | 2,183,000 |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合